|
1
|
Koekkoek PS, Kappelle LJ, van den Berg E,
Rutten GE and Biessels GJ: Cognitive function in patients with
diabetes mellitus: Guidance for daily care. Lancet Neurol.
14:329–340. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miles WR and Root HF: Psychologic tests
applied to diabetic patients. Arch Intern Med (Chic). 30:767–777.
1922. View Article : Google Scholar
|
|
3
|
Mijnhout GS, Scheltens P, Diamant M,
Biessels GJ, Wessels AM, Simsek S, Snoek FJ and Heine RJ: Diabetic
encephalopathy: A concept in need of a definition. Diabetologia.
49:1447–1448. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang XY, Liang J, Chen DC, Xiu MH, Yang
FD, Kosten TA and Kosten TR: Low BDNF is associated with cognitive
impairment in chronic patients with schizophrenia.
Psychopharmacology (Berl). 222:277–284. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Svichar N, Shishkin V, Kostyuk E and
Voitenko N: Changes in mitochondrial Ca2+ homeostasis in
primary sensory neurons of diabetic mice. Neuroreport. 9:1121–1125.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
MacGibbon GA, Cooper GJ and Dragunow M:
Acute application of human amylin, unlike beta-amyloid peptides,
kills undifferentiated PC12 cells by apoptosis. Neuroreport.
8:3945–3950. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ji LN, Pan CY, Lu JM, Li H, Zhu DL, Li Q,
Li QF, Peng YD, Tian HM, Yao C, Zhao ZG, et al: Efficacy and safety
of combination therapy with vildagliptin and metformin versus
metformin uptitration in Chinese patients with type 2 diabetes
inadequately controlled with metformin monotherapy: A randomized,
open-label, prospective study (VISION). Diabetes Obes Metab.
18:775–782. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gao C, Liu Y, Jiang Y, Ding J and Li L:
Geniposide ameliorates learning memory deficits, reduces tau
phosphorylation and decreases apoptosis via GSK3β pathway in
streptozotocin-induced alzheimer rat model. Brain Pathol.
24:261–269. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Selvarajah D and Tesfaye S: Central
nervous system involvement in diabetes mellitus. Curr Diab Rep.
6:431–438. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Darsalia V, Olverling A, Larsson M,
Mansouri S, Nathanson D, Nyström T, Klein T, Sjöholm Å and Patrone
C: Linagliptin enhances neural stem cell proliferation after stroke
in type 2 diabetic mice. Regul Pept. 190–191:25–31. 2014.
View Article : Google Scholar
|
|
11
|
Nassar NN, Al-Shorbagy MY, Arab HH and
Abdallah DM: Saxagliptin: A novel antiparkinsonian approach.
Neuropharmacology. 89:308–317. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
D'Amico M, Di Filippo C, Marfella R,
Abbatecola AM, Ferraraccio F, Rossi F and Paolisso G: Long-term
inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Exp
Gerontol. 45:202–207. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pintana H, Apaijai N, Chattipakorn N and
Chattipakorn SC: DPP-4 inhibitors improve cognition and brain
mitochondrial function of insulin-resistant rats. J Endocrinol.
218:1–11. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Deacon CF: Therapeutic strategies based on
glucagon-like peptide 1. Diabetes. 53:2181–2189. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Deacon CF: Dipeptidyl peptidase-4
inhibitors in the treatment of type 2 diabetes: A comparative
review. Diabetes Obes Metab. 13:7–18. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Messori A, Fadda V, Maratea D, Trippoli S
and Marinai C: Testing the therapeutic equivalence of alogliptin,
linagliptin, saxagliptin, sitagliptin or vildagliptin as
monotherapy or in combination with metformin in patients with type
2 diabetes. Diabetes Ther. 5:341–344. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Drucker DJ and Nauck MA: The incretin
system: Glucagon-like peptide-1 receptor agonists and dipeptidyl
peptidase-4 inhibitors in type 2 diabetes. Lancet. 368:1696–1705.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Matteucci E and Giampietro O: Mechanisms
of neurodegeration in type 2 diabetes and the neuroprotective
potential of dipeptidyl peptidase 4 inhibitors. Curr Med Chem.
22:1573–1581. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pintana H, Tanajak P, Pratchayasakul W,
Sa-nguanmoo P, Chunchai T, Satjaritanun P, Leelarphat L,
Chattipakorn N and Chattipakorn SC: Energy restriction combined
with dipeptidyl peptidase-4 inhibitor exerts neuroprotection in
obese male rats. Br J Nutr. 1–9. 2016.PubMed/NCBI
|
|
20
|
Sripetchwandee J, Pipatpiboon N,
Pratchayasakul W, Chattipakorn N and Chattipakorn SC: DPP-4
inhibitor and PPARγ agonist restore the loss of CA1 dendritic
spines in obese insulin-resistant rats. Arch Med Res. 45:547–552.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kosaraju J, Murthy V, Khatwal RB, Dubalab
A, Chinnic S, Nataraj Muthureddy SK and Basavan D: Vildagliptin: An
anti-diabetes agent ameliorates cognitive deficits and pathology
observed in streptozotocin-induced Alzheimer's disease. J Pharm
Pharmacol. 65:1773–1784. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pipatpiboon N, Pratchayasakul W,
Chattipakorn N and Chattipakorn SC: PPARγ agonist improves neuronal
insulin receptor function in hippocampus and brain mitochondria
function in rats with insulin resistance induced by long term
high-fat diets. Endocrinology. 153:329–338. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pipatpiboon N, Pintana H, Pratchayasakul
W, Chattipakorn N and Chattipakorn SC: DPP4-inhibitor improves
neuronal insulin receptor function, brain mitochondrial function
and cognitive function in rats with insulin resistance induced by
high-fat diet consumption. Eur J Neurosci. 37:839–849. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zheng T, Qin L, Chen B, Hu X, Zhang X, Liu
Y, Liu H, Qin S, Li G and Li Q: Association of plasma DPP4 activity
with mild cognitive impairment in elderly patients with type 2
diabetes: Results from the GDMD study in China. Diabetes Care.
39:1594–1601. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nath S, Ghosh SK and Choudhury Y: A murine
model of type 2 diabetes mellitus developed using a combination of
high fat diet and multiple low doses of streptozotocin treatment
mimics the metabolic characteristics of type 2 diabetes mellitus in
humans. J Pharmacol Toxicol Methods. 84:20–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Proctor CJ and Gray DA: GSK3 and p53-is
there a link in Alzheimer's disease? Mol Neurodegener. 5:72010.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hu S, Begum AN, Jones MR, Oh MS, Beech WK,
Beech B, Yang F, Chen P, Ubeda OJ, Kim PC, et al: GSK3 inhibitors
show benefits in an Alzheimer's disease (AD) model of
neurodegeneration but adverse effects in control animals. Neurobiol
Dis. 33:193–206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ragot K, Delmas D, Athias A, Nury T,
Baarine M and Lizard G: α-Tocopherol impairs
7-ketocholesterol-induced caspase-3-dependent apoptosis involving
GSK-3 activation and Mcl-1 degradation on 158N murine
oligodendrocytes. Chem Phys Lipids. 164:469–478. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ambacher KK, Pitzul KB, Karajgikar M,
Hamilton A, Ferguson SS and Cregan SP: The JNK- and AKT/GSK3β-
signaling pathways converge to regulate puma induction and neuronal
apoptosis induced by trophic factor deprivation. PloS One.
7:e468852012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Qiao HJ, Li ZZ, Wang LM, Sun W, Yu JC and
Wang B: Association of lower serum Brain-derived neurotrophic
factor levels with larger infarct volumes in acute ischemic stroke.
J Neuroimmunol. 307:69–73. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li R, Ma J, Wu Y, Nangle M, Zou S, Li Y,
Yin J, Zhao Y, Xu H, Zhang H, et al: Dual delivery of NGF and bFGF
coacervater ameliorates diabetic peripheral neuropathy via
inhibiting schwann cells apoptosis. Int J Biol Sci. 13:640–651.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
El Batsh MM, El Batch MM, Shafik NM and
Younos IH: Favorable effects of vildagliptin on metabolic and
cognitive dysfunctions in streptozotocin-induced diabetic rats. Eur
J Pharmacol. 769:297–305. 2015. View Article : Google Scholar : PubMed/NCBI
|
